Giovanni Staurenghi

Giovanni Staurenghi

Auto-generated profile, based on publicly available information

Giovanni Staurenghi

Eye Clinic, Department of Biomedical and Clinical Sciences, Ospedale Luigi Sacco, University of Milan, Milan, Italy

Research Focus & Metrics

Academic Career Length

40Years (1987-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2018 in Progress in Retinal and Eye Research
Verified
Journal Article
Open access
RSRichard F. Spaide
Richard F. Spaide
JFJames G. Fujimoto
James G. Fujimoto
NWNadia K. Waheed
Nadia K. Waheed
SSSrinivas R. Sadda
Srinivas R. Sadda
GSGiovanni Staurenghi
Giovanni Staurenghi
Optical coherence tomography (OCT) was one of the biggest advances in ophthalmic imaging. Building on that platform, OCT angiography (OCTA) provides depth resolved images of blood flow in the retina and choroid with levels of detail far exceeding that obtained with older forms of imaging. This new modality is challenging because of the need for new equipment and processing techniques, current limitations of imaging capability, and rapid advancements in both imaging and in our understanding of the imaging and applicable pathophysiology of the retina and choroid. These factors lead to a steep learning curve, even for those with a working understanding dye-based ocular angiography. All for a method of imaging that is a little more than 10 years old. This review begins with a historical account of the development of OCTA, and the methods used in OCTA, including signal processing, image generation, and display techniques. This forms the basis to understand what OCTA images show as well as how image artifacts arise. The anatomy and imaging of specific vascular layers of the eye are reviewed. The integration of OCTA in multimodal imaging in the evaluation of retinal vascular occlusive diseases, diabetic retinopathy, uveitis, inherited diseases, age-related macular degeneration, and disorders of the optic nerve is presented. OCTA is an exciting, disruptive technology. Its use is rapidly expanding in clinical practice as well as for research into the pathophysiology of diseases of the posterior pole.

1 April 2018 in Ophthalmology
Verified
Journal Article
Closed access
SSSRINIVAS R SADDA
SRINIVAS R SADDA
RGRobyn Guymer
Robyn Guymer
FHFrank G. Holz
Frank G. Holz
SSSteffen Schmitz-Valckenberg
Steffen Schmitz-Valckenberg
CCChristine A. Curcio
Christine A. Curcio
GSGiovanni Staurenghi
Giovanni Staurenghi

1 August 2014 in Ophthalmology
Verified
Journal Article
Closed access
GSGiovanni Staurenghi
Giovanni Staurenghi
SSSrinivas Sadda
Srinivas Sadda
UCUsha Chakravarthy
Usha Chakravarthy
RSRichard F. Spaide
Richard F. Spaide

5 September 2014 in British Journal of Ophthalmology
Verified
Journal Article
Open access
PDF file
FHFrank G Holz
Frank G Holz
RTRamin Tadayoni
Ramin Tadayoni
SBStephen Beatty
Stephen Beatty
ABAlan Berger
Alan Berger
MCMatteo G Cereda
Matteo G Cereda
SSSobha Sivaprasad
Sobha Sivaprasad
Background/aims Real-life anti-vascular endothelial growth factor (VEGF) therapy use in patients with wet age-related macular degeneration (wAMD) was assessed in a retrospective, observational study in Canada, France, Germany, Ireland, Italy, the Netherlands, UK and Venezuela. Methods Medical records of patients with wAMD, who started ranibizumab treatment between 1 January 2009 and 31 August 2009, were evaluated. Data were collected until the end of treatment and/or monitoring or until 31 August 2011. Results 2227 patients who received ≥1 anti-VEGF injection with a baseline visual acuity assessment and ≥1 postbaseline visual acuity assessment for the treated eye were evaluated. Visual acuity improved until about day 120; thereafter, visual acuity gains were not maintained. Mean change in visual acuity score from baseline to years 1 and 2 was +2.4 and +0.6 letters, respectively. Patients received a mean of 5.0 and 2.2 injections in the first and second year, respectively. There were substantial differences in visual outcomes and injection frequency between countries. More frequent visits and injections were associated with greater improvements in visual acuity. Conclusions In clinical practice, fewer injections are administered than in clinical trials. Anti-VEGF treatment resulted in an initial improvement in visual acuity; however, this was not maintained over time. Trial registration number NCT01447043.

1 March 1995
Verified
Journal Article
Closed access
FDF C Delori
F C Delori
CDC K Dorey
C K Dorey
GSG Staurenghi
G Staurenghi
OAO Arend
O Arend
DGD G Goger
D G Goger
JWJ J Weiter
J J Weiter

1 April 2011 in Ophthalmology
Verified
Journal Article
Closed access
FHFrank G. Holz
Frank G. Holz
WAWinfried Amoaku
Winfried Amoaku
JDJUAN DONATE-LOPEZ
JUAN DONATE-LOPEZ
RGRobyn Guymer
Robyn Guymer
UKUlrich Kellner
Ulrich Kellner
GSGiovanni Staurenghi
Giovanni Staurenghi